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Abstract
Background and Objective Although acetaminophen is frequently used during pregnancy, little is known about fetal acetami-
nophen pharmacokinetics. Acetaminophen safety evaluation has typically focused on hepatotoxicity, while other events (fetal 
ductal closure/constriction) are also relevant. We aimed to develop a fetal–maternal physiologically based pharmacokinetic 
(PBPK) model (f-m PBPK) to quantitatively predict placental acetaminophen transfer, characterize fetal acetaminophen 
exposure, and quantify the contributions of specific clearance pathways in the term fetus.
Methods An acetaminophen pregnancy PBPK model was extended with a compartment representing the fetal liver, which 
included maturation of relevant enzymes. Different approaches to describe placental transfer were evaluated (ex vivo coty-
ledon perfusion experiments, placental transfer prediction based on Caco-2 cell permeability or physicochemical properties 
 [MoBi®]). Predicted maternal and fetal acetaminophen profiles were compared with in vivo observations.
Results Tested approaches to predict placental transfer showed comparable performance, although the ex vivo approach 
showed highest prediction accuracy. Acetaminophen exposure in maternal venous blood was similar to fetal venous umbili-
cal cord blood. Prediction of fetal acetaminophen clearance indicated that the median molar dose fraction converted to 
acetaminophen-sulphate and N-acetyl-p-benzoquinone imine was 0.8% and 0.06%, respectively. The predicted mean aceta-
minophen concentration in the arterial umbilical cord blood was 3.6 mg/L.
Conclusion The median dose fraction of acetaminophen converted to its metabolites in the term fetus was predicted. The 
various placental transfer approaches supported the development of a generic f-m PBPK model incorporating in vivo placen-
tal drug transfer. The predicted arterial umbilical cord acetaminophen concentration was far below the suggested postnatal 
threshold (24.47 mg/L) for ductal closure.
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Key Points 
A fetal–maternal physiologically based pharmacokinetic 
(f-m PBPK) model has been developed to quantitatively 
predict placental transfer of acetaminophen and char-
acterize fetal acetaminophen exposure and metabolic 
clearance in the fetus at term delivery.
Different approaches for describing placental drug 
transfer (estimation of placental transfer parameters 
from ex vivo cotyledon perfusion experiments, scaling 
of placental transfer via Caco-2 cell permeability, and 
via physicochemical properties  [MoBi® default method]) 
showed broadly comparable performance, although the 
ex vivo approach achieved highest prediction accuracy.
Acetaminophen exposure in the maternal venous blood 
was similar to that in the fetal venous umbilical cord 
blood. In addition, the predicted mean acetaminophen 
concentration, after a maternal dose of 1000 mg, in 
arterial umbilical cord blood, suspected to be involved 
in ductus arteriosus closure/constriction, was 3.6 mg/L 
and therefore far below the suggested postnatal threshold 
(24.47 mg/L).
Prediction of acetaminophen clearance in the fetus 
indicated that the median molar dose fraction of aceta-
minophen converted to acetaminophen-sulphate and 
N-acetyl-p-benzoquinone imine was 0.8% and 0.06%, 
respectively.
1 Introduction
Pregnant women frequently and increasingly take medica-
tion [1]. Irrespective of whether the fetus is the target of 
pharmacotherapy, the fetus is probably exposed to any drug 
taken by the mother [2]. Adequate models to predict fetal 
pharmacokinetic profiles and drug exposure are scarce. 
Physiologically based pharmacokinetic (PBPK) modeling 
can be a valuable tool facilitating the prediction of fetal drug 
exposure [3, 4].
Although 60% of pregnant women take acetaminophen 
(paracetamol) [5], little is known about acetaminophen phar-
macokinetics after therapeutic dosing and the contributions 
of specific metabolic clearance pathways to total clearance 
in the fetus. Acetaminophen is metabolized through different 
metabolic pathways in the liver [6]. In adults, acetaminophen 
is predominantly metabolized via glucuronidation (55%) 
and sulphation (30%). To a smaller extent, acetaminophen 
is excreted unchanged (2–5%) in urine. In addition, a minor 
fraction is metabolized through cytochrome P450 (CYP) 
enzyme-mediated oxidation forming the toxic metabolite 
N-acetyl-p-benzoquinone imine (NAPQI) (5–10%). Under 
normal conditions, NAPQI is immediately neutralized by 
conjugation with glutathione [7]. At high dosages, how-
ever, glutathione will become depleted and NAPQI is held 
responsible for acetaminophen-induced hepatotoxicity [8]. 
Research on acetaminophen toxicity has typically been con-
cerned with hepatotoxicity, whereas other adverse events 
might also be relevant for the fetus and may relate to fetal 
exposure to acetaminophen or its metabolites. Therefore, it 
is important to explore the separate contributions of the dif-
ferent metabolic pathways. Several epidemiological studies 
[9–12] report that perinatal acetaminophen exposure might 
be associated with pulmonary (e.g., atopy) and neurodevel-
opmental (e.g., attention deficit hyperactivity disorder) toxi-
cology. In addition, a recent case series analysis describes 
an association between maternal acetaminophen intake and 
fetal ductus arteriosus constriction or closure [13]. It seems 
unlikely that both hepatic and extrahepatic adverse events 
can be attributed to NAPQI alone, since adverse events can 
also be attributed to acetaminophen [5, 14].
Different approaches to integrate placental drug transfer 
in a fetal–maternal PBPK (f-m PBPK) framework have been 
previously presented [4]. Mathematically, placental transfer 
can be described by a modified form of Fick’s first law of 
diffusion with the two key parameters being the transpla-
cental passive diffusion clearance (Dpl) and partition coef-
ficient between the fetal and maternal compartment (Kf,m). 
Informing these parameters is difficult since they are not 
readily measurable in the in vivo system and hence several 
approaches to estimate these parameters were previously 
reported [4]. These approaches relied on informing the pla-
cental transfer rate and partition coefficient through ex vivo 
cotyledon perfusion experiments [15] or scaling placental 
transfer via Caco-2 cell permeability or physicochemical 
properties  [MoBi® default method] while fixing the parti-
tion coefficient at a value of 1.0 [2, 16]. While some of these 
approaches were evaluated for a limited number of specific 
drugs, they have not yet been carefully compared with each 
other.
This study has two objectives: first, to develop a f-m 
PBPK model that can quantitatively predict placental trans-
fer and drug exposure of acetaminophen in the term fetus 
at delivery and compare the predictive performance of the 
three different approaches to integrate placental drug trans-
fer in a PBPK framework; second, to quantify the hitherto 
unknown contributions of specific metabolic clearance path-
ways to total clearance in the term fetus.
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2  Methods
Figure 1 shows the workflow of the present study. Previ-
ously, a pregnancy PBPK model for acetaminophen and its 
metabolites has been developed and verified [17]. To this 
model structure, we added a fetal liver compartment (Fig. 2). 
Three different methods for informing the two unknown 
parameters of placental transfer (the Dpl and partition coef-
ficient) in a PBPK model were evaluated: (i) estimation of 
the Dpl and partition coefficient from the ex vivo cotyledon 
perfusion experiment [18]; (ii) estimation of the Dpl from a 
previously reported scaling approach via Caco-2 cells while 
fixing the partition coefficient to a value of 1.0 [2, 16]; and 
(iii) estimation of the Dpl from physicochemical properties 
of the drug (default method implemented in  MoBi®) while 
fixing the partition coefficient to a value of 1.0 [3]. Predicted 
acetaminophen pharmacokinetic profiles were compared to 
observed data obtained from the umbilical vein at delivery 
[19]. In addition, acetaminophen (mean) concentrations in 
the arterial umbilical cord blood were predicted for evalu-
ating the risk of possible constriction/closure of ductus 
arteriosus. Finally, the contributions of specific metabolic 
clearance pathways in the term fetus to total clearance were 
both predicted but could not be evaluated due to lack of 
in vivo data.
2.1  Software
PBPK models were built in  MoBi®, part of the Open Sys-
tems Pharmacology software suite (http://www.open-syste 
ms-pharm acolo gy.org). R Studio (version 3.3.0) was used 
for graphics creations and statistical analysis. MONOLIX 
version 4.4.0 (Lixoft, Orsey, France) was used to estimate 
placental transfer parameters of acetaminophen from the 
ex vivo cotyledon perfusion experiment.
2.2  Development of Fetal–Maternal Physiologically 
Based Pharmacokinetic (f‑m PBPK) Models
In a previous study, the development of pregnancy PBPK 
models was successfully verified for the three trimesters 
of pregnancy [17]. In brief, first, a PBPK model was pre-
viously developed for both intravenous and oral acetami-
nophen administration in non-pregnant women. The predic-
tive performance of the model was evaluated by comparing 
simulations with observed in vivo pharmacokinetic profiles 
of acetaminophen, acetaminophen-glucuronide, aceta-
minophen-sulphate, and unchanged acetaminophen after 
both oral and intravenous acetaminophen administration of 
standard dosages [20–22]. Once the non-pregnant PBPK 
model captured the observed pharmacokinetics adequately, 
Fig. 1  Schematic workflow of fetal–maternal physiologically based 
pharmacokinetic (f-m PBPK) model development and evaluation. 
Dcot transcotyledon passive diffusion clearance, Dpl transplacental 
passive diffusion clearance, Kf,m partition coefficient between the fetal 
and maternal compartment, PBPK physiologically based pharmacoki-
netic, PK pharmacokinetics
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all drug-specific parameters were fixed and pregnancy-spe-
cific changes were incorporated. Model performance was 
evaluated by comparing simulations with observed in vivo 
pharmacokinetic profiles of acetaminophen, acetaminophen-
glucuronide, acetaminophen-sulphate, and unchanged aceta-
minophen obtained from third-trimester pregnant women 
[20]. For more detailed information about parameterization 
and validation of the previously developed pregnancy PBPK 
model we refer to Mian et al. [17]. Here, the structure of 
the pregnancy PBPK model was extended by incorporating 
a separate well-stirred compartment representing the fetal 
liver. The fetal liver was connected through the blood flow 
from the venous blood pool of the umbilical cord and that to 
the fetal body. This fetal liver compartment was subdivided 
into four sub-compartments, namely plasma ( pls ), blood 
cells ( bc ), interstitial ( int ), and intracellular ( cell ) space. The 
volume of the fetal body compartment was then reduced 
by the volume (0.14 L) of the compartment representing 
the fetal liver. The full structure of the f-m PBPK model 
is depicted in Fig. 2. The expressions of relevant enzymes 
and acetaminophen metabolism were implemented in the 
intracellular space of the fetal liver. Equations (1–4) were 
used to describe the molar drug amount in each of the four 
sub-compartments of the fetal liver ( N{pls,bc,int,cell} ) (µmol):
where C{pls,bc,int,cell} denotes the molar drug concentration in 
each of the four sub-compartments (µmol/L); Q the absolute 
organ blood flow (L/min); HCT the fetal hematocrit; CvenUC
{bc,pls}
 
(1)
dNbc
dt
= Q ⋅ HCT ⋅
(
CvenUC
bc
− Cbc
)
− fu ⋅ SApls,bc
⋅
(
Pbc,pls ⋅
Cbc
Kbc∶pls
− Ppls,bc ⋅ Cpls
)
,
(2)
dNpls
dt
= Q ⋅ (1 − HCT) ⋅
(
CvenUC
pls
− Cpls
)
− fu ⋅ SApls,int
⋅ Ppls,int
(
Cpls −
Cint
Kint∶pls
)
− fu ⋅ SApls,bc
⋅
(
Ppls,bc ⋅ Cpls − Pbc,pls ⋅
Cbc
Kbc∶pls
)
,
(3)
dNint
dt
= fu ⋅ Ppls,int ⋅ SApls,int ⋅
(
Cpls −
Cint
Kint∶pls
)
− fu
⋅ SAint,cell ⋅
(
Pint,cell ⋅
Cint
Kint∶pls
− Pcell,int ⋅
Ccell
Kcell∶pls
)
,
(4)
dNcell
dt
= fu ⋅ SAint,cell ⋅
(
Pint,cell ⋅
Cint
Kint∶pls
− Pcell,int ⋅
Ccell
Kcell∶pls
)
− C
Enzyme
cell
⋅ Vcell ⋅
kcat ⋅ Kprot∶water ⋅ Ccell
Km + Kprot∶water ⋅ Ccell
,
Fig. 2  Structure of the fetal–maternal physiologically based pharma-
cokinetic (f-m PBPK) model. The four sub-compartments (blood cells, 
plasma, interstitial, and intracellular) for acetaminophen distribution 
in the fetal liver have been visualized separately. Solid lines and closed 
arrows indicate blood flow process, dash–dotted lines and closed arrows 
indicate biliary secretion or movement along the intestine through gastro-
intestinal motility, solid lines and open arrows indicate transport across 
the placenta through passive diffusion, boxes with solid frame indicate 
compartments representing organs available in both non-pregnant and 
pregnant women, and boxes with dashed frame indicate compartments 
representing organs exclusively available in pregnant women
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the molar drug concentration in blood cells and plasma in 
the venous blood of the umbilical cord (µmol/L); fu the frac-
tion unbound of the drug; P the local permeability between 
the respective sub-compartments (cm/min); SA the surface 
area at the interface between the respective sub-compart-
ments (cm²); K the partition coefficient between the respec-
tive sub-compartments; Kprot∶water the partition coefficient 
between protein and water; CEnzyme
cell
 the concentration of the 
drug-metabolizing enzyme in the intracellular space of the 
fetal liver (µmol/L); Vcell the volume of the intracellular 
space of the fetal liver (L); kcat the turnover number of the 
specific enzyme  (min–1); and Km the Michaelis-Menten con-
stant (µmol/L).
The fraction of unbound acetaminophen was assumed 
to be similar between maternal and fetal plasma. The local 
permeabilities, the volume of the intracellular space of the 
fetal liver, and the surface area at the interface between the 
respective sub-compartments were automatically estimated 
using scaling approaches implemented in the software [3]. 
It was assumed that the fetal liver is geometrically similar 
to the adult liver (e.g., that the intracellular volume fraction 
of total liver is similar between fetus and adult). The parti-
tion coefficients between the respective sub-compartments 
as well as those between protein and water were estimated 
from equations described elsewhere [3]. Based on literature 
information discussed later, the enzyme concentration in the 
fetal liver was estimated relative to adult levels. Finally, val-
ues for kcat and Km were taken from the PK-Sim® template 
[17, 23], assuming that acetaminophen and its metabolites 
display the same affinity to fetal and adult enzymes. An 
exception was fetal sulfotransferase (SULT) 1A1, for which 
a Km value of 2.4 mmol/L [24] was used in the model. Renal 
excretion of unchanged acetaminophen by the fetus was not 
accounted for in the model, as we assumed that this is very 
limited anyhow [25]
2.3  Acetaminophen Absorption During Labor 
and Fetal Metabolism in the f‑m PBPK Model
The different elimination pathways of acetaminophen and 
its metabolites were implemented in the model as described 
previously for a pregnancy PBPK in non-laboring women 
[17]. In the present study, the maternal pharmacokinetics 
were predicted in term pregnant women during labor. There 
is some evidence that gastric emptying, gastrointestinal 
motility, and hence drug absorption from the gastrointesti-
nal tract, are slower during labor [26, 27]. This is probably 
due to analgesic treatment with opioids [28], vomiting dur-
ing labor, absent of food intake for a long time [29–31], or 
extreme physical exercise, which in particular delays gastric 
emptying time during labor [32, 33]. Whitehead et al. [29] 
reported a threefold delay in time to maximum concentra-
tion (tmax) in pregnant women (n = 36) during labor when 
compared with 2 h post-delivery women (n = 17) [29]. Based 
on this observation, we applied a threefold increase in gas-
tric emptying in the maternal PBPK model.
2.4  Maturation of Enzymes in the Fetus
One aim of the present study was to characterize the con-
tributions of specific metabolic clearance pathways to total 
clearance in the term fetus, including metabolism by uri-
dine 5ʹ-diphospho-glucuronosyltransferase (UGT), SULT 
and CYP. In the PK-Sim® template for acetaminophen, 
UGT1A1, SULT1A1, and CYP2E1 were implemented as 
the main isoforms for the respective metabolic pathway. Due 
to missing information, detoxification kinetics of NAPQI 
could not be parameterized and it was therefore assumed 
that the concentrations of cysteine and mercapturate together 
are equivalent to that of NAPQI [23]. In the PBPK model, 
fetal enzyme expression, and hence fetal metabolism, was 
accounted for only in the fetal liver, not in other fetal tissues.
2.4.1  Uridine 5′‑Diphospho‑Glucuronosyltransferase (UGT) 
1A1
Studies [34, 35] have shown very low expression and activ-
ity of UGT1A1 in human fetal liver microsomes in the sec-
ond half of gestation (0.1–1% of the adult level). Therefore, 
no fetal UGT1A1 expression was implemented in the PBPK 
model, and hence glucuronidation was not modeled in the 
fetus.
2.4.2  Sulfotransferase (SULT) 1A1 and 1A3
There is a broad consensus that, throughout fetal life until 
birth, SULT1A1 is expressed at a relatively constant level 
of about 100% of the level in adult livers [24, 36–40]. 
SULT1A3 expression is 3- to 10-fold higher than adult liver 
values in fetal liver at term [24, 37, 38, 40]. In the PBPK 
model, SULT1A1 and SULT1A3 expression in the fetal liver 
were lumped together and implemented as a 6.5-fold higher 
than the adult value.
2.4.3  Cytochrome P450 (CYP) 2E1
Contradictory information (see Sect. 4) on fetal changes 
in CYP2E1 has been reported [36]. Most studies reported 
detectable CYP2E1 expression or activity in the third trimes-
ter [36, 41]. Johnsrud et al. [42] reported detectable CYP2E1 
amounts in 80% of third-trimester liver microsomes (16.2% 
of the adult level); therefore, this value was implemented in 
the PBPK model [42].
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2.5  Evaluation of Various Approaches 
for Estimating Unknown Parameters 
of Placental Transfer and Integration 
in Physiologically Based Pharmacokinetic 
Models
Three different methods for informing the two unknown 
parameters (Dpl, Kf,m) of placental transfer in a PBPK model 
were evaluated.
2.5.1  Estimation of Placental Permeability and Partition 
Coefficient from Ex Vivo Cotyledon Perfusion 
Experiment
2.5.1.1 Placenta Perfusion The study protocol was approved 
by the ethics review board of the University Hospitals 
(UZ) Leuven (s54819), Eudra-CT number 2012-004580-
51, ClinicalTrials.gov identifier NCT02622802 [43]. The 
experimental setup and methodology have been published 
previously [18]. Placentas were perfused in a recirculating 
(closed–closed) circuit within 30  min after delivery. An 
intact cotyledon was selected for perfusion and the cor-
responding chorionic artery and vein were cannulated. To 
test maternal–fetal transport, acetaminophen 10 µg/mL was 
perfused in the maternal circulation; this is the concentra-
tion that corresponds with the steady-state concentration at 
clinical use. The fetal (Qf) and maternal (Qm) circulations 
were established at a flow of 6 and 14 mL/min, respectively. 
The mean maternal and fetal reservoir volumes (Vm and 
Vf) were 280 and 284 mL, respectively. Samples from both 
maternal and fetal sides were collected at 0, 3, 6, 10, 15, 20, 
and 30 min, then every 15 min until 150 min, and thereafter 
every 30 min until 210 min after addition of acetaminophen 
to the respective reservoir.
2.5.1.2 Estimation of Placental Transfer Parameters Aceta-
minophen maternal to fetal transfer across the placenta was 
estimated using a four-compartment model structure with 
the cotyledon being split into a maternal and a fetal com-
partment (Fig.  3). The transcotyledon passive diffusion 
clearance (Dcot) was assumed to be equal in both fetal-to-
maternal and maternal-to-fetal direction (i.e., no polarity 
was assumed). Although acetaminophen-glucuronide and 
acetaminophen-sulphate transfer have been investigated 
[18], both metabolites were not implemented as verification 
with in vivo data was not possible. The cotyledon volume 
was assumed to be 58 mL on average [44]. The maternal 
cotyledon volume (Vmp) was assumed to be 23 mL and the 
fetal cotyledon volume (Vfp) 35 mL [44]. Loss of volume 
related to sampling was not corrected for as it was < 10%. 
The model was built in two steps: building (1) a structural 
model and (2) a statistical sub-model [45]. Discrimination 
between different models was made by the likelihood ratio 
test using the Objective Function Value (OFV) (i.e., 2* log 
likelihood), where a decrease in OFV of 3.84 points (p < 0.05 
based on a Chi-squared [χ2] distribution) was considered 
statistically significant, between nested models with one 
additional degree of freedom. Furthermore, goodness-of-
fit plots, individual plots, and relative standard error (RSE) 
were evaluated. Several placental transfer models for aceta-
minophen were tested (e.g., simple passive diffusion, linear 
elimination). For the statistical model, inter-individual vari-
ability was tested for significance on all parameters except 
Vmp and Vfp, as the latter were fixed. Error models (propor-
tional, constant, mixed) were investigated to describe the 
residual unexplained variability. Simulated concentrations 
in the maternal and fetal reservoirs were compared to the 
ex vivo experiment concentrations [18].
Equations (5–8) describing the time-dependent change 
of the molar drug amount in the respective compartment 
(N [µmol]) were used to estimate Dcot (mL/min), Kf,m and 
placental elimination (Kpe)  (min–1).
Equation (5): maternal reservoir
Equation (6): maternal part of cotyledon
(5)dNm
dt
=
(
Qm ×
Nmp
Kf,m
− Qm × Nm
)
Vm
.
Fig. 3  Schematic representation of the ex vivo cotyledon perfusion 
model. Dcot transcotyledon passive diffusion clearance, Kf,m partition 
coefficient between the fetal and maternal compartment, Kpe placental 
elimination, Qf fetal flow rate, Qm maternal flow rate, Vf volume of 
fetal reservoir, Vm volume of maternal reservoir, Vfp volume of fetal 
part of the cotyledon, Vmp volume of maternal part of cotyledon
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Equation (7): fetal part of cotyledon
Equation (8): fetal reservoir
where Q is the flow rate (mL/min) and V the volume (mL), m 
indicates maternal, mp indicates maternal part of placenta, f 
indicates fetus, and fp indicates fetal part of placenta.
2.5.1.3 Upscaling of Transfer Parameters from  the  Ex Vivo 
Perfusion Experiment The estimates of the fitted ex  vivo 
transcotyledon transfer parameters (Dcot, Kf,m) were imple-
mented in the f-m PBPK model after scaling the Dcot to the 
Dpl using Eq. 9:
where Dpl (mL/min) and Dcot (mL/min) represent the Dpl and 
transcotyledon passive diffusion clearance, respectively, and 
Vpl (mL) and Vcot (mL) represent the placental and cotyledon 
volumes, respectively.
2.5.2  Scaling Placental Permeability from Caco‑2 Cell 
Permeability
To estimate placental drug transfer [2, 16], Dpl was scaled 
from the apparent permeability measured across Caco-2 
monolayers and total diffusion parameter of a reference 
substance (midazolam). The mean apparent permeability 
of acetaminophen across Caco-2 monolayers (256 nm/s) 
[46–50] was normalized to that of midazolam and subse-
quently multiplied with the total diffusion parameter of 
midazolam at term, which had been determined previously 
[2, 16]. Since this method was only evaluated for drugs 
transferring the placenta via passive diffusion drugs, a Kf,m 
of 1.0 was assumed for acetaminophen [2, 16].
(6)
dNmp
dt
=
(
Qm × Nm − Qm ×
Nmp
Kf,m
− Dcot × Nmp + Dcot × Nfp
)
Vmp
.
(7)dNfp
dt
=
(
Qf × Nf − Qf ×
Nfp
Kf,m
+ Dcot × Nmp − Dcot × Nfp − Kpe × Vfp × Nfp
)
Vfp
.
(8)dNf
dt
=
(
Qf ×
Nfp
Kf,m
− Qf × Nf
)
Vf
,
(9)Dpl =
Dcot × Vpl
Vcot
,
2.5.3  Scaling Placental Permeability from Physicochemical 
Properties
Another method to estimate placental diffusion is the default 
calculation method already implemented in  MoBi®, which 
assumes that the placental permeability of the drug is the 
same as those across other organ membranes. According 
to this method, the permeability is estimated from physico-
chemical properties of the drug, such as lipophilicity and 
molecular weight [3]. Subsequently, the permeability is mul-
tiplied with the villi surface area (11.8 m2) at the specific 
fertilization age [51], yielding the Dpl. The Kf,m was assumed 
to be 1.0 [52].
It has to be noted that for all three placental transfer 
approaches, no polarity in Dpl was assumed, i.e., Dpl is simi-
lar in both (fetal–maternal [f-m] and maternal–fetal [m-f]) 
directions.
2.6  Evaluation of f‑m PBPK Models
The f-m PBPK models were evaluated by comparing the pre-
dicted acetaminophen concentrations in the maternal and the 
fetal venous umbilical cord blood plasma with in vivo con-
centration data obtained from 34 women and their newborns 
(median gestational age 39 weeks, range 38–40 weeks) fol-
lowing single oral administration of acetaminophen 1000 mg 
at delivery [19]). Umbilical cord samples were collected 
at delivery, 0.5–5.8 h after maternal acetaminophen dos-
ing [19]. The estimated pharmacokinetic parameters for all 
three approaches and the observed pharmacokinetic param-
eters were obtained from the Open Systems Pharmacology 
software. Furthermore, ratios of predicted to observed phar-
macokinetic parameters of acetaminophen were estimated. 
A local sensitivity analysis was performed for the two key 
parameters relevant for placental transfer and the gastric 
emptying time. To this aim, the original value was divided 
or multiplied by 1.3, 2, and 5 [53] and the resulting pharma-
cokinetic profiles were predicted and compared with each 
other.
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3  Results
3.1  Evaluation of Placental Transfer Informed 
by Various Approaches
Table 1 shows the estimated values for the Dpl and the parti-
tion coefficient obtained from the ex vivo cotyledon perfu-
sion model. Figure 4 compares observed to simulated con-
centrations for the ex vivo perfusion model, showing good 
agreement between observed and simulated concentrations. 
Table 2 shows the values for Dpl and Kf,m from the different 
placental transfer approaches.  
3.2  Predictions of Maternal and Fetal In Vivo 
Concentrations
Values for the Dpl and the partition coefficient estimated by 
all three approaches were applied in the PBPK model. For 
the ex vivo cotyledon perfusion experiments, kpe was negli-
gibly small (0.0126 min–1) and estimated with high impre-
cision (residual standard error 229%). Therefore, it was not 
implemented in the model. All placental transfer approaches 
Table 1  Estimated values for placental transfer parameters obtained 
in the ex vivo model
Data are expressed as mean (residual standard error)
Dcot transcotyledon passive diffusion clearance, Kf,m partition coef-
ficient between the fetal and maternal compartment, Kpe placental 
elimination
Drug Dcot (mL/min) Kpe  (min–1) Kf,m
Acetaminophen 36 (81) 0.0126 (229) 0.737 (35)
Fig. 4  Ex vivo observed [19] fetal and maternal acetaminophen concentration compared with fetal and maternal simulated acetaminophen pro-
files in the ex vivo cotyledon perfusion experiment
Table 2  Values for placental transfer parameters, calculated using 
the three different approaches, as implemented in the fetal–maternal 
physiologically based pharmacokinetic model
Dpl transplacental passive diffusion clearance, Kf,m partition coeffi-
cient between the fetal and maternal compartment
Parameter Dpl (mL/min) Kf,m
Ex vivo cotyledon perfusion experiment 403 0.737
Scaling of placental transfer rate via 
Caco-2 cell permeability (according to 
Zhang et al. [2, 16])
4354 1.0
Scaling of placental transfer rate via phys-
icochemical properties  (MoBi® default 
method)
3528 1.0
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adequately described the observed maternal venous blood 
concentrations (Fig.  5a, Table 3). Concerning the fetal 
acetaminophen predictions, the different approaches showed 
broadly comparable performance with respect to observed 
pharmacokinetics. Specifically, the ex vivo cotyledon perfu-
sion approach described the fetal pharmacokinetic param-
eters more accurately (Fig. 5b, Tables 3, 4), while scaling Dpl 
via Caco-2 cell permeability or physicochemical properties 
and keeping Kf,m fixed at 1.0 resulted in predictions that were 
in slightly weaker agreement with observed concentrations 
for the acetaminophen fetal pharmacokinetic parameters 
(Fig. 5b, Tables 3, 4). All predicted umbilical cord concen-
trations resulting from each of the three approaches were 
Fig. 5  Predicted maternal (a) and fetal (b) acetaminophen pharma-
cokinetic profiles in venous umbilical cord plasma following admin-
istration of oral acetaminophen 1000  mg using the three different 
placental transfer approaches described in the text. Predicted maternal 
and fetal plasma acetaminophen pharmacokinetic profiles were com-
pared with observed cord blood concentrations for the maternal dose 
of 1000 mg [19]
Table 3  Comparison between 
observed and predicted 
acetaminophen pharmacokinetic 
parameters
AUC ∞ area under the plasma concentration–time curve from time zero to infinity, CL/F apparent total 
clearance of the drug after oral administration, Cmax maximum concentration, Vd/F apparent volume of dis-
tribution after non-intravenous administration
Parameter Scaling of placental 
transfer rate via 
Caco-2 cell perme-
ability
Scaling of placental 
transfer rate via 
physicochemical 
properties
Ex vivo cotyledon 
perfusion experi-
ment
Observed data [19]
Maternal Fetal Maternal Fetal Maternal Fetal Maternal Fetal
AUC ∞ (mg h/L) 43.5 59.5 43.5 59.4 43.8 43.7 43.7 44.0
Cmax (mg/L) 9.5 12.9 9.43 12.9 9.5 9.3 9.3 9.3
CL/F (L/h/kg) 0.36 0.25 0.36 0.26 0.35 0.35 0.35 0.35
Vd/F (L/kg) 1.08 0.79 1.08 0.79 1.05 1.05 1.04 1.04
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within a 1.5-fold error range and 75% within the 1.25-fold 
error range (Table 4).  
The predicted mean acetaminophen concentration in arte-
rial umbilical cord blood—of relevance to potential ductus 
arteriosus constriction/closure—was 3.6 mg/L.
Because the ex  vivo cotyledon perfusion approach 
described the fetal pharmacokinetic parameters most accu-
rately, data from this approach were used to predict the molar 
dose fraction of acetaminophen converted to its metabolites. 
Prediction of acetaminophen clearance in the fetus indicated 
that the median molar dose fraction of acetaminophen con-
verted to acetaminophen-sulphate and NAPQI were 0.8% 
and 0.06%, respectively (Fig. 6).
3.3  Sensitivity Analysis
The local sensitivity analyses for the two unknown param-
eters describing placental transfer (Kf,m and Dpl) are pro-
vided in Fig. 7. Changes in Kf,m substantially impacted 
the predicted fetal plasma concentrations and thereby the 
Table 4  Ratio of predicted 
to observed acetaminophen 
pharmacokinetic parameters for 
three different placental drug 
transfer approaches
AUC ∞ area under the plasma concentration–time curve from time zero to infinity, CL/F apparent total 
clearance of the drug after oral administration, Cmax maximum concentration, Vd/F apparent volume of dis-
tribution after non-intravenous administration
Parameter Scaling of placental transfer 
rate via Caco-2 cell perme-
ability
Scaling of placental transfer 
rate via physicochemical 
properties
Ex vivo cotyledon per-
fusion experiment
Maternal Fetal Maternal Fetal Maternal Fetal
AUC ∞ 0.99 1.35 0.99 1.35 1.00 0.99
Cmax 1.02 1.39 1.01 1.39 1.02 1.00
CL/F 1.03 0.71 1.03 0.74 1.00 1.00
Vd/F 1.04 0.76 1.04 0.76 1.00 1.00
Fig. 6  Bar graph of the predicted median fractions of metabolite formation from acetaminophen (expressed as percentage of molar acetami-
nophen dose) for a fetus at term (a) and a mean individual pregnant woman at term (b). NAPQI N-acetyl-p-benzoquinone imine
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pharmacokinetic parameters of acetaminophen, while the 
predicted fetal acetaminophen concentration–time profile 
was relatively insensitive to changes in Dpl (Fig. 7). To 
further support the above-mentioned finding, the Kf,m for 
each of the placental transfer approaches was assumed to 
be the same and therefore set at 1.0. From the Electronic 
Supplementary Material (ESM_1) it can be seen that large 
variations in Dpl did not have a significant effect on the pre-
dicted maternal and fetal acetaminophen concentration–time 
profiles, but that Kf,m is the sensitive parameter. However, 
when fixing Kf,m at 1.0, all approaches slightly overesti-
mated fetal acetaminophen concentrations. In addition, the 
sensitivity analysis for gastric emptying time revealed that 
this is a sensitive parameter as well, although the predicted 
pharmacokinetic profile in the mother was only moderately 
sensitive towards changes within a biologically plausible 
range. When dividing and multiplying the value of gastric 
emptying time by a factor of 5 (highest and lowest value in 
the sensitivity analysis), maximum concentration (Cmax) and 
tmax are affected by 47.3% and 55.1%, respectively
4  Discussion
Acetaminophen is one of the most frequently used drugs 
throughout pregnancy. Nevertheless, little is known about 
the pharmacokinetics of acetaminophen and its metabolites 
in the fetus. Relevant issues concerning the two study objec-
tives—estimating the placental transfer and pharmacokinet-
ics of acetaminophen, and contributions of the metabolic 
pathways—are outlined in this section.
Placental transfer and fetal exposure were predicted by 
integrating parameter estimates obtained from three differ-
ent approaches. Subsequently, maternal and fetal pharma-
cokinetic predictions were evaluated using published in vivo 
data. Only one study has been conducted in which mater-
nal and fetal venous umbilical cord blood was collected to 
Fig. 7  Sensitivity analyses illustrating how the predicted fetal aceta-
minophen concentrations responds to variations in either the trans-
placental passive diffusion clearance (Dpl) or partition coefficient 
between the fetal and maternal compartment (Kf,m). The parameter 
values for these two parameters were calculated from the three evalu-
ated approaches: ex vivo cotyledon perfusion experiment (a, b), scal-
ing of placental transfer rate via physicochemical properties  (MoBi® 
default method) (c, d), and scaling of placental transfer rate via 
Caco-2 cell permeability (e, f)
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investigate acetaminophen pharmacokinetics, which were 
used for model evaluation [19]. Tested placental transfer 
approaches showed broadly comparable performance with 
respect to observed pharmacokinetics (Fig. 5, Tables 3, 4). 
All ratios of predicted to observed maternal and fetal phar-
macokinetic parameters were within a 1.25- and 1.5-fold 
error range, respectively (Table 4). This indicates that the 
developed acetaminophen f-m PBPK models can adequately 
predict placental transfer of acetaminophen and the fetal 
pharmacokinetic profile. Specifically, the ex vivo cotyledon 
perfusion approach showed the highest prediction accuracy 
resulting from the lower Kf,m value, which was identified 
through local sensitivity analysis as a sensitive parameter 
driving fetal exposure (Fig. 7, ESM_1). This finding is 
intriguing in that it indicates that, within the range of tested 
parameter values, fetal acetaminophen concentrations are 
not primarily governed by the Dpl (probably because equi-
librium is reached very fast), but rather by the partition-
ing between the maternal blood to maternal plasma and the 
fetal blood to fetal placenta. Hence, at least within the range 
of tested values, the maternal-to-fetal concentration ratio 
at equilibrium (i.e., the partition coefficient) is the critical 
parameter for adequately predicting placental transfer. This 
also implies that the placental barrier is a relatively efficient 
barrier inasmuch it has a lower affinity for acetaminophen 
than blood/plasma.
Since the partition coefficient refers to equilibrium con-
centrations, this finding also suggests that few measure-
ments at steady state in the ex vivo cotyledon perfusion 
experiment may be sufficient for successful integration in a 
PBPK framework. Dpl can be informed on the basis of other 
approaches (e.g., the herein evaluated scaling approaches 
via apparent Caco-2 cell permeability or via physicochemi-
cal descriptors, such as lipophilicity and molecular weight). 
For example, this could indicate that the maternal-to-fetal 
ratios of the cord blood concentration combined with scal-
ing methods for Dpl could be readily used to further investi-
gate placental transfer and fetal exposure to drugs that have, 
similar to acetaminophen, a good permeability and are not 
actively transferred across the placenta by drug transport-
ers. Importantly, scaling Dpl via Caco-2 cell permeability 
or molecular descriptors (as implemented per default in 
 MoBi®) relies on information that is often already avail-
able. In contrast to the integration of information from the 
ex vivo cotyledon perfusion experiments, which is a labori-
ous experiment, these two approaches enable rather simple 
and fast integration into a PBPK model—at least in situa-
tions where Kf,m can be assumed to be 1.0 and where pla-
cental transfer occurs relatively fast. However, the tenfold 
difference in Dpl estimates obtained from the ex vivo coty-
ledon perfusion experiment and the other two approaches 
requires further investigations. While Dpl was not a sensitive 
parameter for acetaminophen, future studies could test high 
permeability compounds with high Kf,m values to generate 
more knowledge about the validity of predicting Dpl via dif-
ferent approaches. Overall, the results of the comparison of 
the different approaches for estimating placental transfer are 
in line with a recently published study on emtricitabine and 
acyclovir that demonstrated that fetal exposure can be ade-
quately predicted when placental transfer is informed either 
by the ex vivo cotyledon experiment or by the approach by 
Liu et al. [54]. Still, more research on other drugs with a Kf,m 
approximating 1.0 and high permeability is clearly needed 
to further build confidence.
The second objective was to quantitatively predict the 
hitherto unknown contributions of specific metabolic clear-
ance pathways to total clearance in the term fetus. Of note, 
transfer of acetaminophen from the fetal organism over the 
placenta (i.e., diffusion back to the mother) can be consid-
ered the main elimination pathway for the fetus (Fig. 6). 
Yet the explicit description of the different fetal elimination 
pathways is highly relevant since one of the metabolic path-
ways (CYP2E1-mediated pathway) is involved in hepato-
toxicity. However, since it seems unlikely that both hepatic 
and extrahepatic adverse events can be attributed to NAPQI 
alone, but also to, for example, acetaminophen itself [14], 
it is important to explore the separate contributions of the 
different metabolic pathways to the total acetaminophen 
(fetal) clearance. Expectedly, as can be seen from Fig. 6, 
the fetal contribution to the total acetaminophen (fetal) clear-
ance (Fig. 6a) is, compared to that of the maternal organism 
(Fig. 6b), very low. As recently shown, fetal ductus arterio-
sus constriction or closure following acetaminophen intake 
by pregnant women is a potential safety concern [14]. The 
presented results show that the acetaminophen concentra-
tion at steady state achieved in the arterial umbilical cord 
blood plasma is 3.6 mg/L. When assuming a same target 
concentration for ductus constriction in the human fetus as 
documented in the fetal rat [55], the  EC50 (concentration 
of drug producing 50% of maximum effect) is 24.47 mg/L. 
This indicates that a much higher concentration of aceta-
minophen is needed to constrict the ductus. However, as 
incidents have been reported [13], it is possible that other 
pathways or compartments (e.g., prostaglandins synthesis in 
placenta) are involved.
Some limitations and assumptions of this analysis need to 
be addressed. Firstly, the fetal sub-model of the PBPK model 
was extended by incorporating a separate compartment rep-
resenting the fetal liver placed between the compartments 
representing venous cord blood and the fetal body. While 
the blood from the venous umbilical cord flows through 
the fetal liver through the ductus venosus, the liver paren-
chyma is mainly supplied by blood through the fetal arte-
ria hepatica. Additionally, unchanged drug may be renally 
excreted in the amniotic fluid and subsequently swallowed 
and re-absorbed. Hence, it is important to note that the 
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herein presented model structure does not fully reflect this 
physiologic reality. Further refinements may be necessary 
for more detailed applications. Furthermore, enzyme expres-
sion in the fetal liver was implemented and informed on the 
basis of available data from literature. Obviously, such a 
knowledge-driven approach is limited by the amount and 
quality of information available in the literature. Although 
most studies [42, 56, 57] reported the presence of CYP2E1 
expression or activity during the third trimester of preg-
nancy, Vieira et al. [58] found no CYP2E1 expression in 
66 fetal livers (ranging from 16 to 40 weeks of gestational 
age) in the second and third trimester. While a lower expres-
sion of CYP2E1 in the fetal liver may be physiologically 
plausible in the third trimester, the herein presented PBPK 
model incorporated a relative high expression (16% of the 
adult level in the liver) because this value translates into the 
maximum NAPQI exposure that might be expected in vivo. 
Hence, the presented model can be biased to overestimation 
of fetal exposure to NAPQI as a worst-case scenario. Sec-
ondly, a limitation of the presented model is that only one 
isoform of each enzyme sub-family (UGT1A1, CYP2E1) 
in the fetal liver is incorporated, while other isoforms may 
also be involved in acetaminophen metabolism. No study 
has reported cord blood concentrations of the metabolites 
of acetaminophen, which complicates proper evaluation of 
the predicted metabolite pharmacokinetic profiles. Thirdly, 
fetal and maternal protein binding of acetaminophen and 
its metabolites were assumed to be the same. For acetami-
nophen and its metabolites this may not be relevant, as all 
compounds are only marginally protein bound. Furthermore, 
due to missing information on glutathione-related enzymes 
in the fetus, the detoxification kinetics of NAPQI could not 
be parameterized and we assumed that the concentration of 
cysteine and mercapturate is equivalent to that of NAPQI. 
Here, more research is needed to inform PBPK models more 
accurately. Fourthly, enzyme expression in the placenta was 
not accounted for in the PBPK model. Syme et al. [59] sys-
tematically reviewed the expression of enzymes in the pla-
centa, recognizing that UGT1A1 messenger RNA (mRNA) 
and protein expression have been undetectable at term. For 
CYP2E1, however, mRNA and protein levels have been 
detected in the placenta from the first trimester onwards. 
This observation raises the question whether NAPQI toxicity 
can also be expected in the placenta, an organ with a vitally 
important function for the fetus. For SULT, little is known 
on placental metabolism [59], although Weigand et al. [60] 
reported no acetaminophen-sulphate in placental tissue 
and maternal and fetal plasma concentrations. In addition, 
it should be emphasized that the current f-m PBPK model 
investigated placenta transfer at term pregnancy. Since pla-
centa morphology and function change radically throughout 
gestation, the presented results are probably not readily scal-
able to earlier stages of pregnancy. Finally, placental transfer 
of all acetaminophen metabolites was not covered in this 
analysis because in vivo data from umbilical cord samples of 
metabolites are lacking throughout different weeks of gesta-
tional age, which precludes the investigation and evaluation 
of fetal exposure to the metabolites of acetaminophen.
5  Conclusion
The developed f-m PBPK model adequately captured mater-
nal and fetal pharmacokinetic profiles of acetaminophen at 
term delivery. Taken together, this study provides important 
insights on placental drug transfer and fetal drug exposure 
that can support future efforts to develop more generic f-m 
PBPK models for different drugs. Ultimately, such f-m 
PBPK models can constitute powerful tools to support 
informed decision-making in the clinical setting when infor-
mation from other sources is lacking or inconsistent.
Acknowledgements The authors would like to thank Dr Gilbert Koch 
for his valuable input related to MONOLIX.
Compliance with Ethical Standards 
Funding For this project, P. Mian was supported by the Sophia Sticht-
ing Wetenschappelijk Onderzoek (SSWO) (S16-08) and received 
a Short Term Minor (STM-2017) Grant from the Stichting Sophia 
Kinderziekenhuis to conduct this research, a travel grant from Eramus 
Trustfonds, and the Dr. Catharine van Tussenbroek, Mevr. Speleers 
Pharmacy grant.
Conflict of interest Paola Mian, Karel Allegaert, Sigrid Conings, Pi-
eter Annaert, Dick Tibboel, Marc Pfister, Kristel van Calsteren, and 
John van den Anker have no conflicts of interest directly related to this 
study. André Dallmann is an employee of Bayer AG, a company which 
is part of the Open Systems Pharmacology (OSP) member team and 
involved in OSP software development.
Open Access This article is licensed under a Creative Commons Attri-
bution-NonCommercial 4.0 International License, which permits any 
non-commercial use, sharing, adaptation, distribution and reproduc-
tion in any medium or format, as long as you give appropriate credit 
to the original author(s) and the source, provide a link to the Creative 
Commons licence, and indicate if changes were made. The images or 
other third party material in this article are included in the article’s 
Creative Commons licence, unless indicated otherwise in a credit line 
to the material. If material is not included in the article’s Creative 
Commons licence and your intended use is not permitted by statu-
tory regulation or exceeds the permitted use, you will need to obtain 
permission directly from the copyright holdestimates of the fitted exer.
To view a copy of this licence, visit http://creat iveco mmons .org/licen 
ses/by-nc/4.0/.
References
 1. Pisa FE, Casetta A, Clagnan E, Michelesio E, Vecchi Brumatti 
L, Barbone F. Medication use during pregnancy, gestational age 
and date of delivery: agreement between maternal self-reports and 
 P. Mian et al.
health database information in a cohort. BMC Pregnancy Child-
birth. 2015;15:310. https ://doi.org/10.1186/s1288 4-015-0745-3.
 2. Zhang Z, Imperial MZ, Patilea-Vrana GI, Wedagedera J, Gaohua 
L, Unadkat JD. Development of a novel maternal-fetal physiologi-
cally based pharmacokinetic model I: insights into factors that 
determine fetal drug exposure through simulations and sensitiv-
ity analyses. Drug Metab Dispos. 2017;45(8):920–38. https ://doi.
org/10.1124/dmd.117.07519 2.
 3. Dallmann A, Ince I, Solodenko J, Meyer M, Willmann S, Eiss-
ing T, et al. Physiologically based pharmacokinetic modeling 
of renally cleared drugs in pregnant women. Clin Pharma-
cokinet. 2017;56(12):1525–41. https ://doi.org/10.1007/s4026 
2-017-0538-0.
 4. Dallmann A, Pfister M, van den Anker J, Eissing T. Physi-
ologically based pharmacokinetic modeling in pregnancy: a 
systematic review of published models. Clin Pharmacol Ther. 
2018;104(6):1110–24. https ://doi.org/10.1002/cpt.1084.
 5. Allegaert K, van den Anker JN. Perinatal and neonatal use 
of paracetamol for pain relief. Semin Fetal Neonatal Med. 
2017;22(5):308–13. https ://doi.org/10.1016/j.siny.2017.07.006.
 6. Flint RB, Mian P, van der Nagel B, Slijkhuis N, Koch BC. Quan-
tification of acetaminophen and its metabolites in plasma using 
UPLC-MS: doors open to therapeutic drug monitoring in special 
patient populations. Ther Drug Monit. 2017;39(2):164–71. https 
://doi.org/10.1097/ftd.00000 00000 00037 9.
 7. Forrest JAH, Clements JA, Prescott LF. Clinical pharmacokinetics 
of paracetamol. Clin Pharmacokinet. 1982;7(2):93–107.
 8. Prescott LF. Kinetics and metabolism of paracetamol and phen-
acetin. Br J Clin Pharmacol. 1980;10(Suppl 2):291S–8S.
 9. Sordillo JE, Scirica CV, Rifas-Shiman SL, Gillman MW, Bun-
yavanich S, Camargo CA, et al. Prenatal and infant exposure to 
acetaminophen and ibuprofen and the risk for wheeze and asthma 
in children. J Allergy Clin Immunol. 2015;135(2):441–8. https ://
doi.org/10.1016/j.jaci.2014.07.065.
 10. Shaheen SO, Newson RB, Ring SM, Rose-Zerilli MJ, Holloway 
JW, Henderson AJ. Prenatal and infant acetaminophen exposure, 
antioxidant gene polymorphisms, and childhood asthma. J Allergy 
Clin Immunol. 2010;126(6):1141–8. https ://doi.org/10.1016/j.
jaci.2010.08.047.
 11. Brandlistuen RE, Ystrom E, Nulman I, Koren G, Nordeng H. Pre-
natal paracetamol exposure and child neurodevelopment: a sib-
ling-controlled cohort study. Int J Epidemiol. 2013;42(6):1702–
13. https ://doi.org/10.1093/ije/dyt18 3.
 12. Liew Z, Ritz B, Rebordosa C, Lee PC, Olsen J. Acetaminophen 
use during pregnancy, behavioral problems, and hyperkinetic 
disorders. JAMA Pediatr. 2014;168(4):313–20. https ://doi.
org/10.1001/jamap ediat rics.2013.4914.
 13. Allegaert K, Mian P, Lapillonne A, van den Anker JN. Maternal 
paracetamol intake and fetal ductus arteriosus constriction or clo-
sure: a case series analysis. Br J Clin Pharmacol. 2019;85(1):245–
51. https ://doi.org/10.1111/bcp.13778 .
 14. McGill MR, Sharpe MR, Williams CD. The mechanism underly-
ing acetaminophen-induced hepatotoxicity in humans and mice 
involves mitochondrial damage and nuclear DNA fragmentation. 
J Clin Investig. 2012;122(4):1574–83. https ://doi.org/10.1172/
JCI59 755.
 15. De Sousa Mendes M, Hirt D, Vinot C, Valade E, Lui G, Pres-
siat C, et al. Prediction of human fetal pharmacokinetics using 
ex vivo human placenta perfusion studies and physiologically 
based models. Br J Clin Pharmacol. 2016;81(4):646–57. https ://
doi.org/10.1111/bcp.12815 .
 16. Zhang Z, Unadkat JD. Development of a novel maternal-fetal 
physiologically based pharmacokinetic model II: verification 
of the model for passive placental permeability drugs. Drug 
Metab Dispos. 2017;45(8):939–46. https ://doi.org/10.1124/
dmd.116.07395 7.
 17. Mian P, van den Anker JN, van Calsteren K, Annaert P, Tibboel D, 
Pfister M, et al. Physiologically based pharmacokinetic modeling 
to characterize acetaminophen pharmacokinetics and N-acetyl-
p-benzoquinone imine (NAPQI) formation in non-pregnant and 
pregnant women. Clin Pharmacokinet. 2019 Jul 25. https ://doi.
org/10.1007/s4026 2-019-00799 -5.
 18. Conings S, Tseke F, Van den Broeck A, Qi B, Paulus J, Amant 
F, et al. Transplacental transport of paracetamol and its phase II 
metabolites using the ex vivo placenta perfusion model. Toxi-
col Appl Pharmacol. 2019;370:14–23. https ://doi.org/10.1016/j.
taap.2019.03.004.
 19. Nitsche JF, Patil AS, Langman LJ, Penn HJ, Derleth D, Wat-
son WJ, et  al. Transplacental passage of acetaminophen in 
term pregnancy. Am J Perinatol. 2017;34(6):541–3. https ://doi.
org/10.1055/s-0036-15938 45.
 20. Allegaert K, Peeters MY, Beleyn B, Smits A, Kulo A, van Cal-
steren K, et al. Paracetamol pharmacokinetics and metabolism 
in young women. BMC Anesthesiol. 2015;15(1):163. https ://doi.
org/10.1186/s1287 1-015-0144-3.
 21. Beaulac-Baillargeon L, Rocheleau S. Paracetamol pharma-
cokinetics during the first trimester. Eur J Clin Pharmacol. 
1994;46(5):451–4.
 22. Mitchell MC, Hanew T, Meredith CG, Schenker S. Effects of oral 
contraceptive steroids on acetaminophen metabolism and elimina-
tion. Clin Pharmacol Ther. 1983;34(1):48–53.
 23. Krauss M, Schaller S, Borchers S, Findeisen R, Lippert J, Kuepfer 
L. Integrating cellular metabolism into a multiscale whole-body 
model. PLoS Comput Biol. 2012;8(10):e1002750. https ://doi.
org/10.1371/journ al.pcbi.10027 50.
 24. Adjei AA, Gaedigk A, Simon SD, Weinshilboum RM, Leeder JS. 
Interindividual variability in acetaminophen sulfation by human 
fetal liver: Implications for pharmacogenetic investigations of 
drug-induced birth defects. Birth Defects Res A Clin Mol Teratol. 
2008;82(3):155–65. https ://doi.org/10.1002/bdra.20535 .
 25. Krekels EH, van Ham S, Allegaert K, de Hoon J, Tibboel D, 
Danhof M, et al. Developmental changes rather than repeated 
administration drive paracetamol glucuronidation in neonates and 
infants. Eur J Clin Pharmacol. 2015;71(9):1075–82. https ://doi.
org/10.1007/s0022 8-015-1887-y.
 26. Galinsky RE, Levy G. Absorption and metabolism of aceta-
minophen shortly before parturition. Drug Intell Clin Pharm. 
1984;18(12):977–9.
 27. Davison JS, Davison MC, Hay DM. Gastric emptying time in 
late pregnancy and labour. J Obstet Gynaecol Br Commonw. 
1970;77(1):37–41.
 28. Kulo A, van Calsteren K, Verbesselt R, Smits A, Devlieger R, de 
Hoon J, et al. The impact of Caesarean delivery on paracetamol 
and ketorolac pharmacokinetics: a paired analysis. J Biomed Bio-
technol. 2012;2012:437639.
 29. Whitehead EM, Smith M, Dean Y, O’Sullivan G. Forum: an eval-
uation of gastic emptying times in pregnancy and the puerperium. 
Anaesthesia. 1993;48(1):53–7.
 30. Holdsworth JD. Relationship between stomach contents and anal-
gesia in labour. Br J Anaesth. 1978;50(11):1145–8.
 31. Nimmo WS, Wilson J, Prescott LF. Narcotic analge-
sics and delayed gastric emptying during labour. Lancet. 
1975;1(7912):890–3.
 32. Singata M, Tranmer J, Gyte GM. Restricting oral fluid and 
food intake during labour. Cochrane Database Syst Rev. 
2013;8:CD003930. https ://doi.org/10.1002/14651 858.CD003 
930.pub3.
 33. Marzio L, Formica P, Fabiani F, LaPenna D, Vecchiett L, Cuc-
curullo F. Influence of physical activity on gastric empty-
ing of liquids in normal human subjects. Am J Gastroenterol. 
1991;86(10):1433–6.
Characterization of Fetal Acetaminophen Exposure and Metabolic Clearance
 34. Kawade N, Onishi S. The prenatal and postnatal development 
of UDP-glucuronyltransferase activity towards bilirubin and the 
effect of premature birth on this activity in the human liver. Bio-
chem J. 1981;196(1):257–60.
 35. Felsher BF, Maidman JE, Carpio NM, VanCouvering K, Woolley 
MM. Reduced hepatic bilirubin uridine diphosphate glucuronyl 
transferase and uridine diphosphate glucose dehydrogenase activ-
ity in the human fetus. Pediatr Res. 1978;12(8):838–40. https ://
doi.org/10.1203/00006 450-19780 8000-00007 .
 36. Hines RN. The ontogeny of drug metabolism enzymes 
and implications for adverse drug events. Pharmacol Ther. 
2008;118(2):250–67. https ://doi.org/10.1016/j.pharm thera 
.2008.02.005.
 37. Vietri M, Pietrabissa A, Mosca F, Rane A, Pacific GM. Human 
adult and foetal liver sulphotransferases: inhibition by mefenamic 
acid and salicylic acid. Xenobiotica. 2001;31(3):153–61. https ://
doi.org/10.1080/00498 25011 00434 81.
 38. Richard K, Hume R, Kaptein E, Stanley EL, Visser TJ, Coughtrie 
MW. Sulfation of thyroid hormone and dopamine during human 
development: ontogeny of phenol sulfotransferases and aryl-
sulfatase in liver, lung, and brain. J Clin Endocrinol Metab. 
2001;86(6):2734–42. https ://doi.org/10.1210/jcem.86.6.7569.
 39. Duanmu Z, Weckle A, Koukouritaki SB, Hines RN, Falany JL, 
Falany CN, et al. Developmental expression of aryl, estrogen, 
and hydroxysteroid sulfotransferases in pre- and postnatal human 
liver. J Pharmacol Exp Ther. 2006;316(3):1310–7. https ://doi.
org/10.1124/jpet.105.09363 3.
 40. Cappiello M, Giuliani L, Rane A, Pacifici GM. Dopamine sulpho-
transferase is better developed than p-nitrophenol sulphotrans-
ferase in the human fetus. Dev Pharmacol Ther. 1991;16(2):83–8.
 41. Ring JA, Ghabrial H, Ching MS, Smallwood RA, Morgan DJ. Fetal 
hepatic drug elimination. Pharmacol Ther. 1999;84(3):429–45.
 42. Johnsrud EK, Koukouritaki SB, Divakaran K, Brunengraber LL, 
Hines RN, McCarver DG. Human hepatic CYP2E1 expression 
during development. J Pharmacol Exp Ther. 2003;307(1):402–7. 
https ://doi.org/10.1124/jpet.102.05312 4.
 43. University Hospital, Gasthuisberg. Transplacental transfer of 
drugs used in pregnant women [ClinicalTrials.gov identifier 
NCT02622802]. National Institutes of Health, ClinicalTrials.gov. 
https ://clini caltr ials.gov. Accessed 14 Jan 2020.
 44. Shintaku K, Arima Y, Dan Y, Takeda T, Kogushi K, Tsujimoto 
M, et al. Kinetic analysis of the transport of salicylic acid, a 
nonsteroidal anti-inflammatory drug, across human placenta. 
Drug Metab Dispos. 2007;35(5):772–8. https ://doi.org/10.1124/
dmd.106.01302 9.
 45. Nguyen TH, Mouksassi MS, Holford N, Al-Huniti N, Freedman 
I, Hooker AC, et al. Model evaluation of continuous data phar-
macometric models: metrics and graphics. CPT Pharmacomet 
Syst Pharmacol. 2017;6(2):87–109. https ://doi.org/10.1002/
psp4.12161 .
 46. Laitinen L, Takala E, Vuorela H, Vuorela P, Kaukonen AM, 
Marvola M. Anthranoid laxatives influence the absorption of 
poorly permeable drugs in human intestinal cell culture model 
(Caco-2). Eur J Pharm Biopharm. 2007;66(1):135–45. https ://doi.
org/10.1016/j.ejpb.2006.09.006.
 47. Khan S, Elshaer A, Rahman AS, Hanson P, Perrie Y, Mohammed 
AR. Systems biology approach to study permeability of paraceta-
mol and its solid dispersion. Int J Pharm. 2011;417(1–2):272–9. 
https ://doi.org/10.1016/j.ijpha rm.2010.12.029.
 48. Yamashita S, Furubayashi T, Kataoka M, Sakane T, Sezaki 
H, Tokuda H. Optimized conditions for prediction of intes-
tinal drug permeability using Caco-2 cells. Eur J Pharm Sci. 
2000;10(3):195–204.
 49. Faassen F, Vogel G, Spanings H, Vromans H. Caco-2 perme-
ability, P-glycoprotein transport ratios and brain penetration of 
heterocyclic drugs. Int J Pharm. 2003;263(1–2):113–22.
 50. Tammela P, Laitinen L, Galkin A, Wennberg T, Heczko R, 
Vuorela H, et al. Permeability characteristics and membrane affin-
ity of flavonoids and alkyl gallates in Caco-2 cells and in phospho-
lipid vesicles. Arch Biochem Biophys. 2004;425(2):193–9. https 
://doi.org/10.1016/j.abb.2004.03.023.
 51. Dallmann A, Ince I, Meyer M, Willmann S, Eissing T, Hempel 
G. Gestation-specific changes in the anatomy and physiology 
of healthy pregnant women: an extended repository of model 
parameters for physiologically based pharmacokinetic modeling 
in pregnancy. Clin Pharmacokinet. 2017;56(11):1303–30. https ://
doi.org/10.1007/s4026 2-017-0539-z.
 52. Robertson RG, Van Cleave BL, Collins JJ Jr. Acetaminophen 
overdose in the second trimester of pregnancy. J Fam Pract. 
1986;23(3):267–8.
 53. Schalkwijk S, Buaben AO, Freriksen JJM, Colbers AP, Burger 
DM, Greupink R, et al. Prediction of fetal darunavir exposure 
by integrating human ex-vivo placental transfer and physiologi-
cally based pharmacokinetic modeling. Clin Pharmacokinet. 
2018;57(6):705–16. https ://doi.org/10.1007/s4026 2-017-0583-8.
 54. Liu XI, Momper JD, Rakhmanina N, van den Anker JN, Green DJ, 
Burckart GJ, et al. Physiologically based pharmacokinetic models 
to predict maternal pharmacokinetics and fetal exposure to emtric-
itabine and acyclovir. J Clin Pharmacol. 2020;60(2):240–55. https 
://doi.org/10.1002/jcph.1515.
 55. Tanaka S, Hori S, Satoh H, Sawada Y. Prediction of fetal ductus 
arteriosus constriction by systemic and local dermatological for-
mulations of NSAIDs based on PK/PD analysis. Int J Clin Phar-
macol Ther. 2016;54(10):782–94. https ://doi.org/10.5414/cp202 
532.
 56. Nishimura M, Yaguti H, Yoshitsugu H, Naito S, Satoh T. Tissue 
distribution of mRNA expression of human cytochrome P450 
isoforms assessed by high-sensitivity real-time reverse transcrip-
tion PCR. Yakugaku Zasshi. 2003;123(5):369–75. https ://doi.
org/10.1248/yakus hi.123.369.
 57. Choudhary D, Jansson I, Stoilov I, Sarfarazi M, Schenkman JB. 
Expression patterns of mouse and human CYP orthologs (fami-
lies 1–4) during development and in different adult tissues. Arch 
Biochem Biophys. 2005;436(1):50–61. https ://doi.org/10.1016/j.
abb.2005.02.001.
 58. Vieira I, Sonnier M, Cresteil T. Developmental expression 
of CYP2E1 in the human liver. Hypermethylation control of 
gene expression during the neonatal period. Eur J Biochem. 
1996;238(2):476–83.
 59. Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism 
by the human placenta. Clin Pharmacokinet. 2004;43(8):487–514. 
https ://doi.org/10.2165/00003 088-20044 3080-00001 .
 60. Weigand UW, Chou RC, Maulik D, Levy G. Assessment of 
biotransformation during transfer of propoxyphene and aceta-
minophen across the isolated perfused human placenta. Pediatr 
Pharmacol (New York). 1984;4(3):145–53.
